Ligand Pharmaceuticals Incorporated — FY2011 Form 10-K
Reporting period: Fiscal year ended December 31, 2011; the filing also reports fourth-quarter results. Ligand is a biotechnology company whose revenues primarily come from partner royalties, license and milestone payments, and CAPTISOL formulation-material sales. The January 2011 CyDex acquisition added CAPTISOL and related programs.
Financial results and liquidity
| Metric | FY2011 | FY2010 |
|---|---|---|
| Total revenue | $30.0 million | $23.5 million |
| Royalties | $9.2 million | $7.3 million |
| CAPTISOL material sales | $12.1 million | None reported |
| Collaborative R&D and other revenue | $8.7 million | $16.3 million |
| Operating loss | $0.7 million | $29.3 million |
| Income (loss) from continuing operations | $10.2 million | $(12.8) million |
| Net income (loss) | $10.2 million | $(10.4) million |
| Cash used in operating activities | $1.2 million | $27.1 million |
Revenue rose 27.6% year over year, reflecting CAPTISOL sales following the CyDex acquisition and higher PROMACTA royalties. Material-sales cost was $4.9 million, implying a 59.5% gross margin on material sales. The overall operating margin was approximately negative 2.3%. Net income included a $13.1 million income-tax benefit; Ligand still recorded an operating loss.
At year-end, cash and cash equivalents were $7.0 million, short-term investments $10.0 million, and restricted cash and investments $1.3 million. Working capital was negative $11.4 million. The balance sheet showed $10.0 million of current bank-line borrowings and $20.3 million of long-term notes payable. Stockholders’ equity was $8.6 million; accumulated deficit was $681.8 million.
Material changes and notable developments
- CyDex was acquired for $31.6 million cash plus contingent consideration. The acquisition contributed $16.2 million of 2011 segment revenue, principally associated with CAPTISOL.
- R&D expense fell to $10.3 million from $22.1 million, mainly because collaborative research agreements had ended. General and administrative expense increased to $15.0 million from $12.8 million, partly due to CyDex operating costs and stock compensation.
- Operating cash use improved substantially versus 2010, but cash flow remained negative. Investing activities used $25.1 million, including the CyDex acquisition; financing activities provided $30.0 million, primarily from debt issuance.
- In January 2012, Ligand borrowed an additional $7.5 million under an expanded Oxford facility and repaid $4.5 million on its Square 1 line. The filing says up to another $2.5 million could be borrowed by April 30, 2012.
- Fourth-quarter 2011 revenue was $12.9 million and continuing-operations income was $4.8 million. The filing does not clearly attribute all quarterly earnings to recurring operations.
Outlook, risks and unusual items
- Management expected cash, investments, and anticipated royalty, license, and milestone receipts to fund operations for at least 12 months. It cited CAPTISOL sales and PROMACTA royalties as potential cash-flow drivers, while noting that forecasts depend on partner performance and development outcomes. No quantified revenue or earnings guidance was provided.
- Key pipeline milestones cited included a planned 2012 pivotal study for CAPTISOL-enabled melphalan; a planned 2012 supplemental filing for PROMACTA in hepatitis C-related thrombocytopenia; and FDA review of Onyx’s carfilzomib NDA, with a July 27, 2012 action date. These were expectations, not assured outcomes.
- Ligand relies on partners for development and commercialization and on Hovione as its sole CAPTISOL supplier. The company said its inventory was expected to cover obligations through 2012 under then-current demand assumptions.
- CyDex CVR holders disputed payment calculations and alleged Ligand exceeded a debt limit in the CVR agreement. Ligand disagreed; unresolved claims could proceed to arbitration. The company paid $4.3 million to CVR holders in January 2012 and could owe additional milestone- and revenue-based payments.
- Ligand reported a material weakness in accounting for significant non-routine transactions, linked to inadequate staffing and CyDex acquisition accounting. It restated its first-, second-, and third-quarter 2011 interim statements. Management and the auditor concluded internal control over financial reporting was ineffective at year-end; the auditor issued an adverse control opinion. The auditor gave an unqualified opinion on the 2011 financial statements.
- Other material exposures include dependence on PROMACTA and AVINZA royalties, AVINZA generic and patent risk, acquisition integration, potential CAPTISOL safety or supply issues, and substantial lease and CVR obligations. The filing also describes prior losses on a commercial-paper investment.
Important facts for investors to verify
- Whether CAPTISOL sales and partner royalties produce sustained positive operating cash flow, rather than relying on financing or one-time items.
- The effect of the $13.1 million tax benefit on reported FY2011 profitability and the durability of future earnings.
- Progress in remediating the material weakness, the reliability of subsequent reporting, and any further restatements.
- Resolution of the CyDex CVR dispute, potential payments, debt covenants, and liquidity after the January 2012 borrowing and line repayment.
- Partner progress and regulatory outcomes for PROMACTA, carfilzomib, melphalan, and other programs; confirm actual milestones against the filing’s projected dates.
- CAPTISOL supply continuity, customer concentration, and exposure to AVINZA royalty declines or generic competition.